论文部分内容阅读
目的 :评价诺和灵 30 R及诺和灵 R- R- R- N治疗糖尿病的临床疗效。方法 :将60例糖尿病患者随机分为诺和灵 30 R组及诺和灵 R- R- R- N治疗组 ,每组各 30例 ,治疗1 5 d后比较两组患者血糖、胰岛素使用剂量。结果 :在控制空腹血糖及早餐后血糖上 ,两组均较治疗前明显下降 ;治疗后两组空腹血糖、餐后血糖差异不显著 ;诺和灵 30 R日用量较诺和灵 R- R- R- N减少。结论 :诺和灵 30 R在治疗糖尿病过程中控制血糖方面与诺和灵 R- R- R- N组无显著差异 ,但日用剂量、注射次数、治疗费用少于诺和灵 R- R- R- N组 ,临床依从性好。
OBJECTIVE: To evaluate the clinical efficacy of Novolin 30 R and Novolin R-R-N in the treatment of diabetes mellitus. Methods: 60 patients with diabetes mellitus were randomly divided into norepinephrine 30 R group and norepinephrine R-R-N group, 30 cases in each group. After 15 days of treatment, the blood glucose and insulin dosage . Results: After controlling fasting blood glucose and postprandial blood glucose, both groups were significantly lower than those before treatment; fasting blood glucose and postprandial blood glucose were not significantly different between the two groups after treatment; R-N decrease. Conclusion: Novolin 30 R has no significant difference with norvenol R-R-N-N in the control of blood glucose during the treatment of diabetes, but the dosage, the number of injections and the cost of treatment are less than that of Novolin R- R-N group, good clinical compliance.